Universal protection of allogeneic cell therapies from natural killer cells via CD300a agonism
Shuqi Zhang, Faith Thomas, Justin W. Fang, Kathryn Austgen, Chad A. Cowan, G. Grant Welstead
This paper develops CD300a TASR, an engineered ligand that universally protects HLA-deficient allogeneic T cells from NK cell rejection and enhances CAR-T efficacy.
Blood Advances · Oct 5, 2024Peer-reviewedImmunology